Jove
Visualize
お問い合わせ
このページは機械翻訳されています。他のページは英語で表示される場合があります。View in English
  1. ホーム
  3. 研究分野
  5. 生物医学と臨床科学
  7. 腫瘍学とがん発生
  9. 予測・予測マーカー
  11. 化学療法による抗腫瘍免疫には,ホルミルペプチド受容体1が必要です.
  1. ホーム
  3. 研究分野
  5. 生物医学と臨床科学
  7. 腫瘍学とがん発生
  9. 予測・予測マーカー
  11. 化学療法による抗腫瘍免疫には,ホルミルペプチド受容体1が必要です.

関連する実験動画

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
09:15

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

4.2K

化学療法による抗腫瘍免疫には,ホルミルペプチド受容体1が必要です.

Erika Vacchelli1, Yuting Ma2, Elisa E Baracco3

  • 1Gustave Roussy Cancer Campus, Villejuif, France. INSERM, U1138, Paris, France. Équipe 11 Labellisée par la Ligue Nationale Contre le Cancer, Centre de Recherche des Cordeliers, Paris, France. Université Paris Descartes, Sorbonne Paris Cité, Paris, France. Université Pierre et Marie Curie, Paris, France.

Science (New York, N.Y.)
|October 31, 2015

PubMed で要約を見る

まとめ
この要約は機械生成です。

甲状腺ペプチド受容体1 (FPR1) 機能喪失アレルは,死滅する癌細胞との dendritic 細胞の相互作用を阻害し,抗腫瘍免疫を低下させることで,化学療法の有効性を損なう. これは,効果的ながん治療への対応において,FPR1の重要な役割を強調しています.

科学分野:

  • 免疫学
  • 腫瘍学
  • 遺伝学

背景:

  • 腫瘍内 dendritic 細胞は抗腫瘍免疫を駆動し,化学療法の有効性を決定する.
  • フォルミルペプチド受容体1 (FPR1) の機能喪失アレルは,補助化学療法を受けている乳がんおよび大腸がん患者の悪い結果と関連しています.

研究 の 目的:

  • 化学療法による抗腫瘍免疫におけるFPR1の役割を調査する.
  • FPR1欠乏がアントラサイクリンベースの化学療法の有効性を損なうメカニズムを解明する.

主な方法:

  • ガン患者におけるホルミルペプチド受容体1 (FPR1) 遺伝子の機能喪失アレルの分析.
  • Fpr1 ((- / -)) がんを持つマウスにおけるアントラサイクリン有効性の評価
  • Fpr1欠乏したモデルにおけるデンドリット細胞機能とT細胞免疫の評価
  • 死亡する癌細胞と白血球の相互作用を研究する微流体装置の実験

主要な成果:

  • FPR1欠乏症は,抗腫瘍免疫が低下したため,マウスのアントラサイクリン治療効果を無効にしました.
  • FPR1欠乏した dendritic 細胞は死にゆく癌細胞に近づき,T細胞媒介の抗腫瘍反応を防ぐことができなかった.
  • FPR1とそのリガンドであるアネキシン-1は,死にゆく癌細胞と白血球の間の安定した相互作用を促進することが確認された.

さらに関連する動画

Novel Protocol for Generating Physiologic Immunogenic Dendritic Cells
12:08

Novel Protocol for Generating Physiologic Immunogenic Dendritic Cells

Published on: May 17, 2019

9.8K
Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care
12:55

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Published on: February 16, 2015

22.2K

関連する実験動画

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
09:15

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

4.2K
Novel Protocol for Generating Physiologic Immunogenic Dendritic Cells
12:08

Novel Protocol for Generating Physiologic Immunogenic Dendritic Cells

Published on: May 17, 2019

9.8K
Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care
12:55

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Published on: February 16, 2015

22.2K

関連する概念動画

Tumor Immunotherapy01:27

Tumor Immunotherapy

2.2K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.2K
The Tumor Microenvironment02:17

The Tumor Microenvironment

8.1K
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
8.1K
Cytotoxic T Cells-mediated Immune Response01:27

Cytotoxic T Cells-mediated Immune Response

8.3K
Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
8.3K
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

748
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates...
748
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

6.3K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.3K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

9.1K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K
JoVE
x logofacebook logolinkedin logoyoutube logo
JoVEについて
概要リーダーシップブログJoVEヘルプセンター
著者向け
出版プロセス編集委員会範囲と方針査読よくある質問投稿
図書館員向け
推薦の声購読アクセスリソース図書館諮問委員会よくある質問
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experimentsアーカイブ
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教員リソースセンター教員サイト
利用規約
プライバシーポリシー
ポリシー

結論:

  • FPR1は,化学療法による有効な抗がん免疫反応に不可欠です.
  • 癌患者の化学療法の有効性を高める戦略として,FPR1またはそのリガンドをターゲットにすることがあります.